(AMLX) – Business Wire
-
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Synd
-
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
-
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
-
Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
-
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
-
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
-
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
-
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference
-
Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
-
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP)
-
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS
-
Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical Officer
-
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MND
-
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx Conference
-
Amylyx Pharmaceuticals Reports Third Quarter 2023 Financial Results
-
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023
-
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research Symposi
-
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
-
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
-
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
-
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
-
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
-
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
-
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
-
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
-
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
-
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
-
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
-
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
-
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
-
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
-
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
-
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
-
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
-
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
-
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
-
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
-
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
-
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
-
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
-
Amylyx Pharmaceuticals Announces Launch of Public Offering
-
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
-
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
-
Amylyx Pharmaceuticals Announces Publication of Preclinical Data Showing Potential Synergistic Effect of AMX0035 Compared to Individual Compounds
Back to AMLX Stock Lookup
